Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,490 across all filing types
Latest filing 2025-04-29 Report Publication Anno…
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
Letter to Registered Shareholders - Notice of publication of 2024 Annual Report
Report Publication Announcement Classification · 99% confidence The document is a short letter to shareholders dated 30 April 2025 notifying them that the 2024 Annual Report is now available on the company’s and Stock Exchange’s websites. It provides instructions on how to access the report and request printed copies. It does not contain financial data or the report itself but merely announces its publication. This matches the definition of a Report Publication Announcement (RPA).
2025-04-29 English
VOLUNTARY ANNOUNCEMENT 707 Injection (Anti-VEGF/PD-1 Bispecific Antibody) Granted Breakthrough Therapy Designation by NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by 3SBio Inc. regarding the granting of Breakthrough Therapy Designation by China’s National Medical Products Administration. It does not present financial results, regulatory form requirements, management changes, or detailed report content. It serves as a general corporate/regulatory update. This aligns with a generic regulatory filing announcement. Therefore, the correct classification is RNS (Regulatory Filings).
2025-04-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Share Issue/Capital Change Classification · 87% confidence The document is the standardized HKEX Form FF301 “Monthly Return for Equity Issuer … on Movements in Securities.” It provides detailed movements in authorised, issued, and treasury shares, including share option exercises and funds raised. This is not an earnings announcement or annual report but a routine regulatory return focused solely on share capital changes. Thus it falls under Share Issue/Capital Change (SHA).
2025-04-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025
Regulatory Filings Classification · 90% confidence The document is a standard Hong Kong Exchange Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts under Chapter 19B,” reporting monthly movements in authorized and issued share capital. It is a routine regulatory return submitted to the exchange, not an annual or interim report, earnings release, board change, or proxy statement. It does not announce a dividend or share issue, nor is it a transcription or presentation. Therefore it falls into the fallback category for miscellaneous regulatory filings.
2025-04-01 English
FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
Annual Report Classification · 100% confidence The document is titled 'FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024' and contains comprehensive consolidated financial statements, including the Statement of Profit or Loss, Statement of Comprehensive Income, and Statement of Financial Position, along with detailed notes on accounting policies and segment information. As it provides full-year financial performance data for the fiscal year ending December 31, 2024, it qualifies as an Annual Report (10-K equivalent for this jurisdiction). FY 2024
2025-03-28 English
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2024
Notice of Dividend Amount Classification · 92% confidence The announcement is clearly titled “Cash Dividend Announcement for Equity Issuer” and provides detailed information on a final dividend for the year ended 31 December 2024, including dividend per share, ex-dividend date, record date, book close period, and payment date. This matches the definition for Notice of Dividend Amount (DIV) – an announcement of dividend amounts, payment dates, and related details.
2025-03-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.